Lupin Launches Luforbec® 100/6 μg pMDI, first branded generic alternative to Fostair® 100/6 μg pMDI for treatment of Asthma & COPD, in the UK

Lupin Healthcare (UK) Limited, wholly-owned subsidiary of global pharma major Lupin Limited (Lupin), today announced that following the Medicines and Healthcare products Regulatory Agency (MHRA) approval earlier this year, it has launched Luforbec® (beclometasone / formoterol) 100/6 dose pressurised metered dose inhaler (pMDI), making it available now to patients in the UK, with the potential to offer significant cost savings for the NHS.

Luforbec® is indicated for the treatment of adult asthma and for the symptomatic treatment of severe chronic obstructive pulmonary disease (COPD) (FEV1 <50% predicted normal).

Lupin is approved to manufacture Luforbec at its sites in Pithampur in India and Coral Springs in the US. In the twelve months to May 2021, the NHS spent over £177 million on Fostair® 100/6 pMDI.

Shares of Lupin Ltd was last trading in BSE at Rs. 924.75 as compared to the previous close of Rs. 928.5. The total number of shares traded during the day was 128368 in over 6088 trades.

The stock hit an intraday high of Rs. 940.35 and intraday low of 915. The net turnover during the day was Rs. 119145594.

Source : Equity Bulls

Keywords